ENDO-205 Moves Toward Human Testing as a Non-Hormonal Peptide for Endometriosis

Endometriosis has resisted simple solutions because it is not merely misplaced tissue or an isolated pain disorder. It is a chronic inflammatory disease in which tissue resembling the uterine lining grows outside the uterus, often producing pelvic pain, heavy bleeding, infertility and scar formation. The World Health Organization estimates that it affects about 190 million women of reproductive age worldwide. Yet hormone-suppressing medicines, pain treatment and surgery remain the principal tools, and none constitutes a definitive cure. Against that landscape, an experimental peptide called ENDO-205 has attracted attention for a different proposition: attack diseased lesions while attempting to leave normal hormonal function intact.

That proposition is compelling, but ENDO-205 is not an approved treatment and has not been shown to eliminate endometriosis in people. It is an investigational candidate developed by EndoCyclic Therapeutics, formerly identified in federal grant records as Endomet Biosciences. In March 2026, the company announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application, allowing a Phase 1 program to begin. IND clearance means regulators have permitted human testing under a submitted protocol. It is not FDA approval, proof of efficacy or confirmation that a medicine is safe for general use.

Aiming beyond hormonal suppression

Existing hormonal therapies can reduce endometriosis-associated pain by limiting ovarian hormone production or altering hormonal signaling. These approaches can help many patients, but symptoms may return when treatment ends, and some regimens can cause menopausal symptoms, bone-density loss or other adverse effects. They can also conflict with near-term pregnancy goals. Surgical excision can remove visible lesions and may provide meaningful relief, but recurrence and persistent pain remain possible.

ENDO-205 is being developed as a non-hormonal, disease-modifying alternative. EndoCyclic describes a cell-permeating, pH-sensitive peptide platform intended to concentrate activity in diseased tissue. The company says the candidate is selectively absorbed by endometriosis lesions and engages an intracellular disease pathway, with the goal of causing lesions to regress while preserving normal reproductive cycling. An NIH RePORTER record for the federally supported development program similarly describes selective uptake in endometriosis tissue and reports lesion regression or disappearance without disruption of estrous cycling in preclinical work.

The public evidence, however, remains incomplete. The developer has reported efficacy in laboratory and animal studies and no identified safety signal in completed good-laboratory-practice toxicology work. Detailed peer-reviewed data establishing the magnitude, durability and reproducibility of those effects are not yet available in the human clinical literature. Public descriptions also do not fully disclose the peptide’s sequence, dosing strategy or complete intracellular target profile. Those omissions are understandable during drug development, but they limit independent assessment.

Why the biological idea is plausible

Endometriosis lesions survive through a network of inflammatory, hormonal, fibrotic and cell-migration pathways. Research has repeatedly implicated abnormal Wnt and beta-catenin signaling in lesion growth, invasion and fibrosis. In experiments using cells obtained from patients, inhibition of the TCF/beta-catenin complex reduced migration and invasion. Other studies have found dysregulated beta-catenin activity in endometriosis tissue. These findings support the broader idea that a targeted intracellular intervention could change lesion behavior without globally suppressing estrogen.

They do not prove that ENDO-205 will work. A biologically credible target can still fail because a candidate does not reach enough tissue, produces unexpected toxicity, is cleared too quickly, behaves differently across lesion subtypes or fails to improve symptoms that matter to patients. Pain can also persist through nerve sensitization and other mechanisms even when lesion burden changes. A successful trial program will therefore need to measure more than lesion appearance.

What Phase 1 must establish

The company has said its first study is planned in healthy premenopausal women of reproductive age. Such a trial would ordinarily focus on safety, tolerability, pharmacokinetics and the relationship between dose and exposure, rather than proving that the drug treats endometriosis. Later studies in patients would need controlled comparisons and clinically meaningful endpoints: pelvic pain, menstrual pain, quality of life, lesion burden, fertility-related outcomes, recurrence and the durability of any response after dosing stops.

Investigators will also need to examine immune reactions, reproductive safety, off-target effects and whether pH-sensitive targeting is sufficiently selective in humans. Endometriosis is heterogeneous; superficial peritoneal disease, ovarian endometriomas and deep infiltrating lesions may not respond identically. A therapy that reaches one lesion type may perform differently in another.

ENDO-205 therefore deserves attention as a serious experimental program, not as a cure waiting on a calendar. Its non-hormonal design addresses an important limitation in current care, and reported preclinical lesion clearance is a meaningful reason to watch the clinical transition. The decisive evidence will come from well-controlled human studies. Until those results exist, ENDO-205 should be described accurately: a promising investigational peptide entering the earliest stage of human development, not a proven treatment for endometriosis. That caution is especially important when hopeful headlines travel faster than clinical evidence.